window.pageData = {"stock":{"_id":3000000007005,"stockCode":"007005","stockType":"fund","areaCode":"cn","followedNum":3,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":7005,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药C","fundSecondLevel":"company","fundStatus":"normal","inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundFlag":null,"activeFundFlag":null,"classificationFlag":null,"closedEnd":null,"etfFundFlag":null,"feederFundFlag":null,"indexFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"pinyin":"zjxyygpxzqtzjj","fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50960000","tickerId":50960000,"name":"中金基金管理有限公司"},"managers":[{"name":"丁天宇","stockType":"fund_manager","stockCode":"db20782834","exchange":"fm","tickerId":42025209810}],"hotMetrics":{"fss":{"stockId":3000000007005,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0,"f_ind_h_s_r":1,"f_h_a":2381,"f_h_s_a":5842,"f_ind_h_s_r_c_1y":0,"f_ind_h_s_r_c_hy":0,"f_ins_h_s_r_c_1y":0,"f_ins_h_s_r_c_hy":0,"last_data_date":"2025-06-29T16:00:00.000Z"},"fpr":{"stockId":3000000007005,"type":"fpr","f_p_r_fys_ssc":5552,"f_p_r_fys_ssrp":0.7029364078544407,"f_p_r_m1_ssc":5944,"f_p_r_m1_ssrp":0.47097425542655225,"f_p_r_m3_ssc":5768,"f_p_r_m3_ssrp":0.674180683197503,"f_p_r_m6_ssc":5525,"f_p_r_m6_ssrp":0.723388848660391,"f_p_r_y1_ssc":4807,"f_p_r_y1_ssrp":0.7619642114024137,"f_p_r_y2_ssc":3627,"f_p_r_y2_ssrp":0.8466629895201324,"f_p_r_y3_ssc":2930,"f_p_r_y3_ssrp":0.8791396381017412,"f_p_r_y5_ssc":1858,"f_p_r_y5_ssrp":0.8928379106085084,"f_cagr_p_r_fs_ssc":6035,"f_cagr_p_r_fs_ssrp":0.6145177328471992},"fp":{"stockId":3000000007005,"type":"fp","f_p_r_fys":-0.05282041060394638,"f_p_r_m1":0.020326367019753766,"f_p_r_m3":-0.03277020150620791,"f_p_r_m6":-0.0646896732712241,"f_p_r_y1":-0.0009110659471579519,"f_p_r_y3":-0.13147313269160354,"f_cagr_p_r_fs":0.0510266069341212,"f_p_r_d1":0.004456054087277117,"f_p_r_y2":0.11235955056179847,"f_p_r_y5":-0.40844018424000794,"last_data_date":"2026-06-28T16:00:00.000Z","f_i_d":"2019-05-13T16:00:00.000Z"},"ff":{"stockId":3000000007005,"type":"ff","f_m_f":762343,"f_m_f_r":0.012,"f_c_f":127057,"f_c_f_r":0.002,"f_m_a_c_f":889400,"f_m_a_c_f_r":0.014,"f_m_c_f_d":"2024-06-29T16:00:00.000Z","f_c_fr":0.002,"f_fr_d":"2026-05-21T16:00:00.000Z","f_m_fr":0.012,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000007005,"type":"f_nlacan","f_nv_d":"2026-06-28T16:00:00.000Z","f_nv":1.4256,"f_nv_cr":0.060162117944522864},"f_as":{"stockId":3000000007005,"type":"f_as","f_tas":16786897.277400002,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj"}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":600276,"holdings":121800,"marketCap":6725796,"netValueRatio":0.0865,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":963,"holdings":160500,"marketCap":5668860,"netValueRatio":0.0729,"quarterlyChange":-0.1046894803548798,"stock":{"stockCode":"000963","exchange":"sz","stockType":"company","tickerId":963,"name":"华东医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":603259,"holdings":51300,"marketCap":5032530,"netValueRatio":0.0647,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":300347,"holdings":92500,"marketCap":4979275,"netValueRatio":0.064,"quarterlyChange":-0.050617283950616376,"stock":{"stockCode":"300347","exchange":"sz","stockType":"company","tickerId":300347,"name":"泰格医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":1000000000001801,"holdings":47500,"marketCap":3560716,"netValueRatio":0.0458,"quarterlyChange":0.11344262295081897,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":300358,"holdings":362700,"marketCap":3413007,"netValueRatio":0.0439,"quarterlyChange":-0.03881511746680244,"stock":{"stockCode":"300358","exchange":"sz","stockType":"company","tickerId":300358,"name":"楚天科技"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":688212,"holdings":90917,"marketCap":3391204,"netValueRatio":0.0436,"quarterlyChange":-0.1466483642187142,"stock":{"stockCode":"688212","tickerId":688212,"exchange":"sh","stockType":"company","name":"澳华内镜"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":688266,"holdings":31311,"marketCap":3093526,"netValueRatio":0.0398,"quarterlyChange":0.06580366774541457,"stock":{"stockCode":"688266","tickerId":688266,"exchange":"sh","stockType":"company","name":"泽璟制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":1000000000006990,"holdings":7273,"marketCap":2953979,"netValueRatio":0.038,"quarterlyChange":0.17287098419173907,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000006981,"stockId":688301,"holdings":27112,"marketCap":2946803,"netValueRatio":0.0379,"quarterlyChange":0.07496785678963458,"stock":{"stockCode":"688301","tickerId":688301,"exchange":"sh","stockType":"company","name":"奕瑞科技"}}]},"list":[{"_id":"69e8ead51398d79843fe8bc7","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000006981,"sao":"2026年一季度医药行业整体呈现前低后高走势。1月、2月整体承压，3月创新药强势反弹，带动医药行业上涨。万得全A指数一季度下跌1.15%，申万医药生物指数一季度下跌0.90%，行业相对跑赢大盘0.25个百分点，在申万31个一级行业中排名第18位，表现中等。板块内部呈现结构性分化特征，创新药表现突出，但传统板块持续承压，行业内部估值与业绩分化显著。2026年前三个月BD总额接近600亿美金，创新药公司收入高增长，头部biopharma逐步进入盈利阶段，诸多利好因素拉动创新药上涨。CXO板块受益于全球医药研发需求复苏与国内创新药出海热潮，头部企业业绩显著增长；其余板块表现不佳。当前位置对比历史，医药板块整体还处于较低位置，我们认为中长期维度医药板块仍然具备配置价值，随着关注度的提升，我们认为医药板块有机会迎来修复行情，所以本基金维持较高的仓位运作。　　报告期加仓了回调较为充分、确有基本面支撑的优质创新药标的。减仓业绩低预期的生命科学上游以及医疗机械。由于各细分赛道内部标的持续分化，我们根据基本面变化持续地进行结构调整。　　展望未来，宏观层面经济温和复苏但结构分化，市场层面估值修复延续，外资流入与融资余额增长支撑市场活跃度，基金经理对A股保持偏乐观观点。从中长期产业发展趋势看，政策宽松与技术创新为主要驱动力；医药行业在政策支持、创新研发和出海BD、以及AI引领的新技术推动下，或持续出现结构性机会，我们将对有望底部反转的细分行业以及产业逻辑较好的创新药产业链保持重点关注。中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，积极配置中长期成长逻辑好、有业绩支撑的优质公司，弱化对估值的要求，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","lastUpdated":"2026-04-22T15:35:49.108Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1479032","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0429","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-01-21T16:00:00.000Z","stockId":3000000006981,"sao":"上证指数四季度上涨2.22%，医药生物指数下跌9.25%，在申万一级行业中排名靠后，整体板块表现弱于大盘。具体来看，2025年第四季度医药板块整体表现承压，细分板块呈现显著分化特征：申万三级行业医药流通指数逆势上涨9.50%，成为唯一正收益细分领域，其余细分领域均下跌超过10%。当前位置对比历史，医药板块整体还处于较低位置，我们认为中长期维度医药板块仍然具备配置价值，随着关注度的提升，我们认为医药板块有机会迎来修复行情，所以本基金维持较高的仓位运作。本报告期内医药板块内各细分板块表现同质性较强：创新药有所回调，创新药产业链上下游标的回调幅度相对接近；医疗器械虽招投标回暖，但三季报业绩拐点未得到验证，持续下跌；中药等稳健类资产业绩承压相对抗跌，但依然表现不佳。　　从中长期产业发展趋势看，我们依然配置在有望底部反转的医疗器械以及产业逻辑较好的创新药产业链上，重新做了个股的梳理和调整。小幅加仓了回调较为充分、确有基本面支撑的优质创新药标的。由于各细分赛道内部标的持续分化，我们根据基本面变化持续地进行结构调整。　　展望未来，后续或持续出台利好政策，我们对A股保持偏乐观观点，积极配置中长期成长逻辑好、有业绩支撑的优质公司，弱化对估值的要求。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","lastUpdated":"2026-03-09T13:25:26.132Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1458885","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0428","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000006981,"sao":"2025年第三季度A股主要指数整体上行，创业板和科创板表现尤为亮眼，医药板块相对上证指数基本跑平。具体来看，医药板块在2025年7月延续上涨，之后整体呈现震荡趋势。板块关注度提升，公募基金配置小幅上升。当前位置对比历史，医药整体还处于较低位置，我们认为中长期维度医药仍然具备配置价值，虽然创新药涨幅较大带动医药指数上涨，但医药其他细分板块资产大多处于较低位置，随着医药关注度的提升，我们认为医药有机会迎来修复行情，所以本基金维持较高的仓位运作。具体来看，医药板块内各细分板块分化持续加大，结构性机会值得把握。创新药在本报告期有所回调，但创新药产业链有较大涨幅。医疗器械招投标回暖，有望进入业绩拐点期，较底部有所上涨。中药等稳健类资产业绩承压依然表现不佳。　　报告期内，我们对持仓向进攻方向做了一些倾斜。从中长期产业发展趋势，我们筛选有望底部反转的医疗器械以及产业逻辑较好的创新药产业链进行配置，加仓了业绩出现向好拐点的创新药产业链相关标的，以及招投标回暖、有望进入业绩拐点期的医疗器械。减仓了涨幅较大，预期较满的创新药标的。由于各细分赛道内部标的持续分化，我们根据基本面变化持续地进行结构调整。　　展望未来，后续或持续出台利好政策，我们对A股保持偏乐观观点，积极配置中长期成长逻辑好、有业绩支撑的优质公司，弱化对估值的要求。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","lastUpdated":"2026-03-09T13:25:26.127Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1379217","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0427","date":"2025-06-29T16:00:00.000Z","stockId":3000000006981,"sao":"2025年上半年A股主要指数整体震荡上行，医药板块相对上证指数跑赢。具体来看，医药板块在2025年上半年整体呈现震荡上行趋势，板块关注度提升，公募基金配置小幅上升。当前位置对比历史，医药整体还处于较低位置，我们认为中长期维度医药仍然具备配置价值，虽然创新药涨幅较大带动医药指数上涨，但医药其他细分板块资产大多处于较低位置，随着医药关注度的提升，我们认为医药有机会迎来修复行情，所以本基金维持较高的仓位运作。具体来看，医药板块内各细分板块分化持续加大，结构性机会值得把握。创新药及创新药产业链均有较大涨幅。中药等稳健类资产、医疗器械业绩承压表现不佳，AI医疗一季度大幅上涨后二季度回撤较大。　　报告期内，我们对持仓向进攻方向做了一些倾斜。从中长期产业发展趋势，我们筛选有望底部反转以及产业逻辑较好的创新药进行配置，加仓了有政策支持、有出海逻辑的创新药标的，以及业绩出现向好拐点的创新药产业链相关标的。减仓了业绩承压的标的以及稳健类标的。由于各细分赛道内部标的持续分化，我们根据基本面变化持续地进行结构调整。","declarationDate":"2025-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.123Z","mo":"展望未来，后续或持续出台利好政策，我们对A股保持偏乐观观点，积极配置中长期成长逻辑好、有业绩支撑的优质公司，弱化对估值的要求。同时，在当前创新药领涨的行情中，我们也积极关注医药行业内其他底部细分赛道边际好转可能带来的投资机会。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1344818","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0426","date":"2025-03-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内上证指数主要呈现横盘震荡盘整走势，单季度小幅收跌0.48%。医药板块相对上证指数跑赢，申万医药指数单季度收涨2.29%。具体来看，医药板块在2025年一季度整体呈现震荡上行趋势，创新药及AI医疗领涨。当前位置对比历史，医药整体还处于较低位置，我们认为中长期维度医药或已经具备配置价值，公募基金非医药基金的持仓比例持续下降，筹码结构向好，所以本基金维持较高的仓位运作。具体来看，医药板块内各细分板块分化持续加大，结构性机会值得把握。创新药及创新药产业链、AI相关主题概念股均有较大涨幅。中药等稳健类资产、医疗器械业绩承压表现不佳。　　报告期内，医药利好政策刺激下，市场对医药的关注度回升，我们对持仓向进攻方向做了一些倾斜。从中长期产业发展趋势，我们筛选有望底部反转以及产业逻辑较好的创新药，我们加仓了业绩已经出现向好拐点的创新药产业链相关标的、底部反转标的、业绩持续高增标的。减仓了可能受到美国关税影响的出口标的，以及稳健类标的。由于各细分赛道内部标的持续分化，我们根据基本面变化持续地进行结构调整。　　展望未来，后续或持续出台利好政策，我们对A股保持偏乐观观点，积极配置中长期成长逻辑好，有业绩支撑的优质公司，弱化对估值的要求。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","declarationDate":"2025-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.120Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2025年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1275390","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0425","date":"2024-12-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内上证指数主要呈现宽幅震荡向上走势，全年收涨12.67%。医药板块相对上证指数跑输较多，申万医药指数全年收跌-14.33%，相对上证指数跑输27%。具体来看，医药板块在2024年整体呈现下跌趋势，部分时段呈现主题投资行情和个股行情。当前位置对比历史，医药整体还处于较低位置，中长期维度医药或已经具备配置价值，公募基金非医药基金的持仓比例持续下降，筹码结构向好，所以本基金维持较高的仓位运作。具体来看，医药板块内各细分板块分化持续加大，结构性机会值得把握。创新药及创新药产业链、低估值稳健标的中均有表现不错的个股，同时也有跌幅较大的个股，对精选个股要求提高。医疗器械业绩承压、表现不佳。并购重组标的依然值得重视。　　报告期内，从中长期产业发展趋势，底部反转以及业绩和估值匹配角度进行选股，我们加仓了业绩已经出现向好拐点的创新药产业链相关公司，底部反转的公司，业绩持续高增长的标的，以及低估值稳健标的。减仓了可能受到美国关税影响的出口标的，对股价预期相对充分的稳健类标的进行了获利了结。由于各细分赛道内部标的持续分化，我们不断的根据基本面变化进行结构调整。","declarationDate":"2025-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.117Z","mo":"展望未来，后续或持续出台利好政策，我们对A股转为偏乐观，积极配置中长期成长逻辑好，有业绩支撑的优质公司，弱化对估值的要求。院内刚需用药、医疗设备在三季度后进入低基数阶段，随着后续招标、诊疗量恢复，预计在2025年逐步兑现到业绩上。创新药中长期发展趋势不变，精选有预期差的优质标的。中药OTC多家公司业绩超预期，未来仍有望持续兑现良好业绩，景气度较高。院内产品受益板块性销售费用下降，利润存在超预期可能，业绩相对稳健，可关注。晶体、电生理等高景气赛道业绩持续兑现，但个股分化也在加大，需要更精细化的选股。骨科、原料药、生命科学上游等赛道回调幅度较大，可关注左侧机会。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1248651","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0424","date":"2024-09-29T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内上证指数主要呈现V字型走势，医药板块相对上证指数跑赢，主要是9月底的上涨行情中表现优于大盘。具体来看，医药板块在2024年三季度大部分时间内整体呈现下跌趋势，在9月最后一周大幅反弹。当前位置对比历史，医药整体还处于较低位置，我们认为中长期维度医药已经具备配置价值，公募基金非医药基金的持仓比例持续下降，筹码结构向好，所以维持较高的仓位运作。医药板块结构性机会依然存在，分化持续加大。创新药及创新药产业链、消费医疗在上涨行情中表现亮眼，本报告期内涨幅居前。医疗器械业绩承压、表现不佳。中药、国企改革标的等防御属性较强的标的上涨行情中弹性不足，表现平平。　　展望未来，我们认为，后续持续出利好政策的概率较大，对A股转为偏乐观，积极配置中长期成长逻辑好，有业绩支撑的优质公司，弱化对估值的要求。马上进入三季报业绩期，我们认为后续基本面优质、有中长期成长逻辑和业绩支撑的标的将会迎来表现。通过中报观察，院内刚需销售占主要的Pharma和Bio-Pharma中报表现不错，大部分公司中报后为利空出尽，三季报值得继续关注。院内刚需用药、医疗设备在三季度将进入低基数阶段，随着后续招标、诊疗量恢复，预计将逐步兑现到业绩上。创新药中长期发展趋势不变，精选有预期差的优质标的。中药OTC多家公司业绩超预期，未来仍有望持续兑现良好业绩，景气度较高。电生理等高景气赛道业绩持续兑现，继续看好，但个股分化也在加大，需要更精细化的选股。骨科、原料药、生命科学上游等赛道回调幅度较大，可关注左侧机会。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","declarationDate":"2024-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.114Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2024年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1179955","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0423","date":"2024-06-29T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内上证指数主要呈现震荡走势，医药板块相对上证指数大幅跑输。具体来看，医药板块在2024年上半年整体呈现下跌趋势，只在4月有所反弹。当前位置对比历史，医药整体还处于较低位置，我们认为中长期维度医药已经具备配置价值，公募基金非医药基金的持仓比例持续下降，筹码结构向好，所以维持较高的仓位运作。尽管上半年医药板块负收益较为明显，但结构性机会依然存在，分化持续加大。业绩稳健，有较高股息率的中药及国企改革相关的标的有所表现，业绩承压的同类标的有所下跌。创新药板块中现金流好的标的涨幅居前，包括已上市品种快速放量的标的和产品海外授权落地的标的，而尚未形成良好现金流且市值包含较高预期的品种跌幅较大。器械、CXO、上游、消费医疗表现较差。受到药品比价系统的影响，药店出现大幅回调。","declarationDate":"2024-07-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.111Z","mo":"展望未来，我们认为，较难有板块性整体机会，板块内个股会持续分化，对择股能力提出更高的要求。从上半年的行情复盘来看，我们认为今年投资者非常重视现金流以及当期业绩的兑现度，对于相对远期的预期并不能给与较高的溢价。因此我们也按此思路进行了相应的调仓，加大了现金流较好、业绩较好的标的配置。中药OTC相关标的估值较低，预期业绩增长较好，中长期看仍然具备性价比。创新药、IVD赛道等成长板块仍处于高速发展阶段，深度回调情绪回暖后表现可期，精选业绩兑现度高的优质个股。内镜方向下半年有望迎来拐点。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1152377","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0422","date":"2024-03-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内上证指数主要呈现震荡走势，医药板块相对上证指数大幅跑输。具体来看，医药板块在2024年1季度呈现下跌趋势。当前位置对比历史，医药整体还处于较低位置，我们认为中长期维度医药已经具备配置价值，所以维持较高的仓位运作。尽管1季度医药板块负收益较为明显，但结构性机会依然存在。创新药、中药及国企改革相关的标的、部分高值耗材、药房和流通等均有所表现。与院内相关的药品、器械等标的表现不佳。CXO、上游、消费医疗表现较差。展望未来，我们认为，较难有板块性整体机会，板块内个股会持续分化，对择股能力提出更高的要求。我们认为今年基本面驱动因素对行情影响更加重要。院内刚需医疗药品、高值耗材，反腐的冲击相对较小；创新药、内镜赛道等成长板块仍处于高速发展阶段，深度回调情绪回暖后表现可期。中药OTC、药店，相关标的估值较低，预期业绩增长较好，中长期看仍然具备性价比。院内产品可能会有板块性销售费用下降带来的利润超预期机会，值得重点关注。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","declarationDate":"2024-04-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.108Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2024年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1074484","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0421","date":"2023-12-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内上证指数主要呈现下跌趋势，医药板块同样有比较明显的负收益。从相对收益角度来看呈现前低后高走势。2023年9月前板块呈现震荡下行走势，一直跑输上证综指。经历了医疗反腐不断发酵后的下跌，医药行业从9月开始跑赢大盘。　　尽管2023年整体市场和医药板块表现较弱，但结构性机会依然存在。创新药、中药及国企改革相关的标的业绩较好，政策支持，涨幅居前。CXO表现落后，龙头公司开启价格战抢夺订单，行业可能由杀估值阶段进入杀基本面的阶段。消费医疗整体表现不佳，市场对于偏高端的消费信心不足，且消费医疗的标的整体估值较高。受到采购节奏影响，器械设备等标的表现不佳。　　全年来看，本基金精选高景气、基本面向上的细分赛道，均衡配置在持续高增长的高景气板块以及基本面触底改善的低估值板块。","declarationDate":"2024-01-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.105Z","mo":"行业可预见的重大利空基本都已反映，展望未来，我们认为医药板块的配置时点已到。结构上看，我们倾向于配置在院外市场、刚需用药以及产业逻辑较强的赛道上，部分降低反腐对经营带来的长期影响。中药或值得配置，政策上有一定倾斜，估值依然较低，改革成效显现，业绩持续平稳增长，部分标的股息率较高。创新药公司的研发能力不断提升，liscence out的机会增多，打开国际市场，同时国内政策支持创新发展，支付体系不断完善下，业绩兑现有望超预期。　　中长期看，医药行业的景气度，人口老龄化趋势下医保基金及个人医疗支出持续增长，医药行业内部顺应改革方向，国产厂商进口替代的大趋势不变。我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1056559","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0420","date":"2023-09-29T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内上证指数主要呈现下跌趋势，医药板块相对上证指数跑赢。具体来看，医药板块的超额收益表现在2023年3季度呈现前低后高的情况。7月由于医疗反腐的不断发酵，医药行业在各行业涨跌幅中排名居后，8月企稳后9月又大幅跑赢。当前位置对比历史，医药整体还处于较低位置，我们仍然看好医药行情的持续性，因此我们依然维持较高的仓位运作。尽管3季度整体市场和医药板块仍是负收益，但结构性机会依然存在。创新药及相关产业链涨幅居前。其中与GLP-1靶点、NASH、阿尔兹海默适应症相关的标的表现更加突出。中药及国企改革相关的标的出现回调，超额收益相比上半年有所收窄。受到反腐影响，与院内相关的药品、器械等标的表现不佳。当前时点展望未来，市场关注的是反腐对于上市公司业绩影响的程度。事件从7月底开始发酵， 8月普遍都显示出对经营不同程度的影响，我们认为重要的观察时点是三季报。结构上看，我们倾向于配置在院外市场、刚需用药以及产业逻辑较强的赛道上，以降低反腐对经营带来的长期影响。短期医疗反腐对行业有一些情绪冲击，基本面影响的大小还需要跟踪后面执行的程度，长期来看，医疗需求不会因为反腐而消失，我们会考虑在下跌中回补一些错杀的标的。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","declarationDate":"2023-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.103Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2023年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=990895","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a041f","date":"2023-06-29T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内医药板块除了有2-3周的反弹之外，整体上半年几乎是单边下跌的走势，医药板块相对上证指数跑输。上半年，医药版块于申万31个一级行业中排名21，处于后1/3。对比历史，医药整体还处于较低位置，我们仍然看好医药行情的持续性，因此我们依然维持较高的仓位运作。尽管上半年整体市场和医药板块表现较弱，但结构性机会依然存在。中药及国企改革板块、院内复苏板块、软镜设备等业绩较好，政策支持的标的涨幅居前。创新药因个股差异较大，有所分化，但整体表现也是不错的。CXO表现落后，龙头公司开启价格战抢夺订单，行业可能由杀估值阶段进入杀基本面的阶段。消费医疗整体表现不佳，市场对于偏高端的消费信心不足，且消费医疗的标的整体估值较高。我们从2023年一季报的分析中，寻找全年主线，对基本面强劲、业绩可持续高增长的细分赛道进行配置。本报告期我们小幅增加了中药及国企改革的标的，以及院内医疗产品等领域的配置，小幅减仓了创新产业链标的。进入中报期，我们会密切关注相关上市公司的业绩变化情况。","declarationDate":"2023-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.099Z","mo":"结构上看，中药或值得配置，政策上有一定倾斜。国企改革值得关注，寻找基本面能够改善的个股。成长类标的，中长期快速可持续增长的标的依然是我们关注的重点，业绩持续兑现的情况下，估值提升空间或较大。我们也在回调中逐步加仓一些优质的创新药标的和院内复苏的相关标的。CXO板块经过整体的估值下移，我们认为现阶段估值基本合理，持续关注上市公司业绩的变化。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=965054","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a041e","date":"2023-03-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内医药板块相对上证指数跑输，在各行业中涨幅居后，在经历2022年四季度的一波上涨行情后有所修整。当前位置对比历史，医药整体还处于较低位置，我们仍然看好医药行情的持续性，因此我们依然维持较高的仓位运作。目前，我们关注的几条医药板块主线均有所表现，中药、设备等业绩较好，政策支持的赛道股涨幅居前。创新药表现分化严重，主要因为部分创新药公司销售不及预期，研发进展、海外拓展时点推迟等原因。CXO表现落后，主要因为部分公司业绩平平叠加股东低位减持等负面因素。我们认为当前应该密切关注2023年一季报的情况，从中寻找基本面强劲、业绩可持续高增长的细分赛道进行配置。本报告期我们小幅增加了自主可控进口替代的标的，以及院内医疗产品等领域的配置，小幅减仓了创新产业链标的。　　结构上看，中药或值得配置，政策上有一定倾斜。国企改革值得关注，寻找基本面能够改善的个股。成长类标的，中长期快速可持续增长的标的依然是我们关注的重点，业绩持续兑现的情况下，估值提升空间或较大。我们也在底部区域逐步加仓一些优质的龙头和成长性较好的细分赛道，比如高壁垒医疗设备、生命周期早期的制药上游产业链、科研仪器等新赛道、消费医疗行业等。CXO板块经过整体的估值下移，我们认为现阶段估值基本合理，未来板块内会出现分化，力争挑选未来3年以上可维持相对高增长的公司进行配置。　　中长期看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","declarationDate":"2023-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.097Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2023年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=883347","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a041d","date":"2022-12-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内医药板块经历了几次大的波动，整体来看2022年前三季度呈现震荡下行走势，第四季度开始，由于一系列的利好政策刺激，叠加前期跌幅深、下跌时间长以及行业配置低等底部特征，医药板块有一波不错的反弹行情，相对上证指数超额收益明显，在各行业中涨幅居前。全年来看，本基金精选高景气、基本面向上的细分赛道，均衡配置在持续高增长的高景气板块以及基本面触底改善的低估值板块。高景气板块包括医美、品牌OTC等；创新产业链包括研发外包、上游供应商，创新器械等。低估值板块包括中药，传统制药等。","declarationDate":"2023-01-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.094Z","mo":"展望2023年，医药整体还处于估值相对较低位置。我们仍然看好医药行情的持续性，因此我们依然维持较高的仓位运作。结构上看，中药或值得配置，政策上有一定倾斜，估值依然较低，业绩持续平稳增长。因医药集采受挫的传统龙头白马股，逐步走出业绩下滑期，找到第二成长曲线。成长类标的，如果医药有上涨行情，估值提升空间或较大。我们也在持续关注成长性较好的细分赛道，比如高壁垒医疗设备、生命周期早期的制药上游产业链等新赛道、消费医疗行业等。经过整体估值的下移，我们认为CXO板块现阶段估值基本合理，未来板块内会出现分化，力争挑选未来3年以上仍然可以维持高增长的公司进行配置。　　中长期看，医药行业的景气度，人口老龄化趋势下医保基金及个人医疗支出持续增长，医药行业内部顺应改革方向，国产厂商进口替代的大趋势不变，专精特新的细分赛道小龙头标的丰富。我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=872086","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a041c","date":"2022-09-29T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内医药板块二次探底，我们认为底部区域基本确立。相比历史，医药很多公司估值已经处于合理状态，但并没有明显高估的状况，与其他行业比较，经过这一轮的下跌后，医药在各个板块中逐渐具备性价比，因此我们依然维持较高的仓位运作。从基本面来看，医药板块的需求在疫情以及后疫情复苏情况下都表现出了较强的刚性和韧性，很多成长性较好的细分赛道以及优质龙头标的的业绩仍然维持较好的增速。我们也在底部区域逐步的加仓了一些优质的龙头和成长性较好的细分赛道，比如高端医疗设备等新赛道，消费医疗行业等。Cxo板块经过整体的估值下移，我们认为现阶段估值基本合理，未来板块内会出现分化，需要挑选未来3年以上仍然可以维持高增长的公司进行配置。9月以来，医药政策出现了一定程度的改善，也为板块的向上行情提供了一定的支撑。  往后看，在行业调整充分、机构持仓低、估值不贵且基本面改善的情况下，我们依然对医药板块的基本面情况保持乐观，依然有信心。结构上看，我们依然会顺应改革方向，选择受益的方向去投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","declarationDate":"2022-10-25T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.090Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2022年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=810158","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a041b","date":"2022-06-29T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内整体市场环境弱市震荡，医药板块在各一级行业中处于落后位置。纵向来看，很多医药公司估值已经处于合理状态，并没有明显高估的状况；横向比较，经过这一轮的反弹，医药在各个板块中相对较弱，因此我们依然维持较高的仓位运作，并且配置时更注重标的的进攻性。持仓主要集中在高增长的高景气行业，包括研发外包、生命科学上游供应商，高壁垒医疗器械，消费医疗；以及部分相对低估值，基本面稳健，同时具有一定边际改善和催化的中药等。  从基本面来看，医药板块的需求在疫情以及后疫情复苏情况下都表现出了较强的刚性和韧性，很多成长性较好的细分赛道以及优质龙头标的的业绩仍然维持较好的增速。我们也在底部区域逐步加仓了一些优质的龙头和成长性较好的细分赛道。Cxo板块（研发生产外包服务供应商）经过整体的估值下移，我们认为现阶段估值基本合理，未来板块内会出现分化，需要挑选未来3年以上仍然可以维持高增长的龙头公司进行配置。在板块疲弱的情况下，我们会更注重自下而上精选个股，挑选有积极变化的个股进行配置。","declarationDate":"2022-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.087Z","mo":"当前时点，结合估值，基本面以及交易面情况，我们对医药板块保持乐观。结构上看，我们依然会顺应改革方向，选择受益的方向进行投资，我们重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=786616","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a041a","date":"2022-03-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内医药板块1月份经历了相对大盘较大幅度的超额下跌，之后开始企稳反弹，2、3月相对收益较为明显。整体市场环境弱市震荡，因此本基金配置兼具进攻性的同时，也注重下跌时的安全边际。持仓集中度中等，主要集中在高估值高增长的高景气行业，包括研发外包、科研服务和生命科学上游供应商；以及部分相对低估值，基本面稳健，同时具有一定边际改善和催化的中药、流通、原料药等。","declarationDate":"2022-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.084Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2022年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=728750","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0419","date":"2021-12-30T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内医药板块经历了几次大的波动，整体来看2021年上半年表现较好，春节后经过美债利率等宏观因素影响，板块下跌回调之后出现了比较大的反弹。下半年医药板块表现较差，整体呈下行趋势。上半年，本基金配置以高弹性品种为主，持仓主要集中在高估值高增长的高景气行业，包括消费升级逻辑相关板块——新增医疗需求、民营医院、品牌OTC；创新产业链——研发外包、创新器械。下半年兑现了部分收益较高的品种，减仓了出现负面政策预期的医疗服务和消费医疗品种，同时新增配置了部分相对低估值、基本面相对稳健的中药，流通股等作为防御，并适当降低重点公司持仓集中度。","declarationDate":"2022-01-23T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.081Z","mo":"2022年，稳增长大背景下，医药板块短期并非市场关注热点，板块高景气赛道估值较高，基本面受到政策、国际环境、流动性因素等扰动，短期股价或承压。因此，我们在持仓结构上进行了调整，降低高估值高增长的高景气赛道的配置比例，增加了低估值、基本面稳健甚至边际变化向好的细分板块的配置。中长期看，医药行业的景气度，人口老龄化趋势下医保基金及个人医疗支出持续增长，医药行业内部，政策鼓励的方向，国产厂商进口替代的大趋势不变，专精特新的细分赛道小龙头标的丰富，调整过后，我们依然维持板块看好的观点，也会择机精选高景气度、相对高确定性、估值合理的优质公司加仓。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=715357","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0418","date":"2021-09-29T16:00:00.000Z","stockId":3000000006981,"sao":"7月之后到8月底，医药板块个股先后出现了不同幅度的调整。此轮调整是多因素促成的，一方面七月前医药整体涨幅居前，其次资金流向当时相对性价比更高的半导体和新能源，最后是大家对政策担忧引起了恐慌。我们认为医保局成立之后，医药处在正确的改革道路之上，国家也给予了肯定，受损和受益的方向也比较明确，我们一直强调医药行业未来是结构性机会。基于此判断，我们认为市场总会回归理性。9月医药板块顺利迎来了一波小反弹，基本确认了医药板块的底部区间。短期来看，医药逐渐走出底部的趋势基本确立，能否走出大的上涨行情还需要一些其他因素的配合，比如新能源，周期还可能时不时抽走一些资金，使得医药板块的上涨趋势中会有一些波动。中长期看，我们对医药板块的基本面情况保持乐观，依然有信心。结构上看，我们会顺应改革方向，选择受益的方向去投资，重视景气度的可持续时间，未来3-5年持续高景气的赛道依然是我们的重点投资方向。下跌中逐渐加仓的景气度高且可持续性强的细分赛道比如cxo，医疗消费；依然看好生命周期早期的高壁垒高值耗材和制药上游产业链。特专新精的小龙头符合国家大战略方向，我们认为优选真正有壁垒，空间大，业绩三年高增长的公司逢低加仓，未来依然会有不错的表现。","declarationDate":"2021-10-26T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.077Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2021年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=657657","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0417","date":"2021-06-29T16:00:00.000Z","stockId":3000000006981,"sao":"报告期内经过美债利率等宏观因素影响，板块下跌回调之后出现了比较大的反弹。本基金选取消费升级逻辑相关板块——新增医疗需求、民营医院、品牌OTC；中长期维持高景气度的创新产业链——创新药、研发外包、创新器械；以及国产替代进程加速相关板块——医疗设备、高端医疗器械等领域的优质企业进行重仓配置。同时由于今年宏观环境、流动性政策、国内外关系的复杂性、各行业政策等不确定性，配置了部分相对低估值、基本面稳健的药店和IVD（体外诊断）作为防御。适当降低重点公司持仓集中度。","declarationDate":"2021-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.072Z","mo":"经过三个月左右的反弹，整体医药行业已经有不少公司股价创新高，估值也处于相对高位，百年建党庆典之后，下半年回调风险加大，适当兑现部分收益。但基于医药行业中长期的景气度、人口老龄化趋势下医保基金及个人医疗支出持续增长，医药行业内部，政策鼓励创新，支持国产厂商替代进口，丰富新专精的细分赛道小龙头，我们依然维持板块看好的观点，择机精选高景气度、相对高确定性的优质公司加仓。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2021年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=635668","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0416","stockId":3000000006981,"sao":"报告期内主要受美债利率等宏观因素影响，板块呈现先涨后跌态势。本基金选取中长期维持高景气度的创新产业链——创新药、研发外包、创新器械；国产替代进程加速相关板块——医疗设备、IVD以及消费升级逻辑相关板块——新增医疗需求、民营医院、品牌OTC等领域的优质企业进行重仓配置。同时由于今年宏观环境，流动性政策，国内外关系的复杂性，配置了部分相对低估值，基本面稳健的药店及血制品作为防御。适当降低重点公司持仓集中度。","date":"2021-03-30T16:00:00.000Z","declarationDate":"2021-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.068Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2021年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=574830","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0415","stockId":3000000006981,"sao":"报告期内主要受医保局政策影响，国内外新冠疫情影响，板块呈现先涨后跌态势。本基金选取中长期维持高景气度的创新药、研发外包、创新器械，国产替代进程加速中的医疗设备、IVD以及消费升级逻辑下的新增医疗需求，民营医院，品牌OTC等领域的优质企业进行重仓配置，基本规避了医保控费、带量采购等相关政策影响较大的仿制药产业链、辅助用药及中成药等板块。对于重点公司持仓集中度较高。","date":"2020-12-30T16:00:00.000Z","declarationDate":"2021-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.064Z","mo":"经过2020年疫情的影响，2021年经济复苏预期较强，医药行业相对比较优势减弱，但中长期基本面依然强劲。进入60岁后，医疗需求会大幅上涨，到2035年，大部分行业人口红利逐渐消失，老龄化+需求升级趋势下，医药行业面临未来二十年的人口结构红利，比较优势明显。需求需要最终支付才能兑现，医药行业单一最大支付方医保基金支出持续增长，行业增量博弈而非存量博弈。行业内部结构分化，蕴藏巨大结构性机会。政策对医药行业影响深远，控费是主基调，控费的目的是调结构，引导企业回归医药本质，因此医药的投资也应回归真实的医疗需求，而非寻找政策漏洞。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2020年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=560124","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0414","stockId":3000000006981,"sao":"报告期内主要受国内外新冠疫情影响，市场及板块波动较大。本基金选取疫情正向影响及短中长期发展趋势向上的原料药及制剂出口、器械、创新药及疫苗、药品研发外包、血制品等领域的优质企业以及布局创新药及器械并获得研发进展的公司进行重仓配置，基本规避了医保控费、带量采购等相关政策影响较大的仿制药板块及辅助用药影响的中药等板块。对于重点公司持仓集中度较高。","date":"2020-09-29T16:00:00.000Z","declarationDate":"2020-10-27T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.056Z","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2020年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=493746","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aeca467fea5b3eb04a0413","stockId":3000000006981,"sao":"报告期内主要受国内外新冠疫情影响，市场及板块波动较大。本基金选取疫情正向影响的原料药&制剂出口、\t器械、创新药&疫苗、药品研发外包、血制品药房等领域的优质企业以及布局创新药及器械并获得研发进展的公司进行重仓配置，基本规避了医保控费、带量采购等相关政策影响较大的仿制药板块及辅助用药影响的中药等板块。对于重点公司持仓集中度较高。","date":"2020-06-29T16:00:00.000Z","declarationDate":"2020-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:25:26.049Z","mo":"展望下半年，中美关系扰动、新冠疫情高位震荡、疫苗研发成功及产能快速放大有望缓解疫情及经济因素。与此同时，为了恢复经济活力而加大流动性投入，加大政策对冲力度，有利于新经济和双循环政策也是可以预期的。医药行业内部，新冠疫情的影响是直接而显著的。疫苗研发成为未来关注重点，21年开始兑现利润，其他细分领域逐步恢复；中长期看，鼓励创新、产业升级、消费升级、全球化依然是最重要的逻辑主线，我们对产业趋势的判断和龙头公司的竞争力判断没有调整，抓住此次疫情机会的公司提升竞争力。我们继续看好药品和器械里具备研发创新能力的细分领域龙头，看好研发外包产业链、消费属性公司、数字化、医疗服务公司。","fund":{"_id":3000000006981,"stockCode":"006981","stockType":"fund","areaCode":"cn","followedNum":17,"blackenedNum":0,"status":"normal","exchange":"jj","fundType":"stock","ipoDate":"2019-04-07T16:00:00.000Z","setUpScale":422860000,"market":"a","tickerId":6981,"custody":"中国建设银行股份有限公司","name":"中金新医药股票型证券投资基金","shortName":"中金新医药(006981)","fundSecondLevel":"company","__csrcFundId":6198,"fundStatus":"normal","lastUpdated":"2026-04-30T20:28:20.570Z","masterFundFlag":1,"inceptionDate":"2019-05-13T16:00:00.000Z","fundCollectionId":4000050960000,"currency":"CNY","masterFundShortName":"中金新医药","memoNum":1,"pinyin":"zjxyygpxzqtzjj","managers":[{"stockCode":"db20782834","stockType":"fund_manager","exchange":"fm","tickerId":42025209810,"name":"丁天宇"}]},"announcement":{"linkText":"中金新医药股票型证券投资基金2020年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=460482","linkType":"PDF","source":"csrc_pdf"}}]}